TRANSLATIONAL REQUIREMENTS FOR ENHANCED CHARACTERISATION OF MANUFACTURED DOPAMINERGIC NEURONS FOR THE TREATMENT OF PARKINSON'S DISEASECYTOTHERAPYIF3.22018-05-011PREAI
The productivity limit of manufacturing blood cell therapy in scalable stirred bioreactorsJOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINEIF2.62017-04-0325OAAI
ENABLING HUMAN PLURIPOTENT STEM CELL DERIVED MEGAKARYOCYTE MANUFACTURECYTOTHERAPYIF3.22016-06-010PREAI
The Global Cell Therapy Industry Continues to Rise during the Second and Third Quarters of 2012CELL STEM CELLIF20.42012-12-0118OAAI
未登录.png){kind=icon}
未登录
